Key result
A high CHA2DS2-VASc score (≥6) was independently associated with an increased risk of all-cause mortality compared to a low score (<6) in CKD patients hospitalized with ACS (HR 2.02).
Why the study?
CKD patients have a high prevalence of CAD and cardiovascular events, prompting assessment of the CHA2DS2-VASc score for predicting mortality in CKD patients hospitalized with ACS.
Does a high CHA2DS2-VASc score predict all-cause mortality in hospitalized ACS patients with CKD?
Cohort (n=313)
No
Does a high CHA2DS2-VASc score predict all-cause mortality in hospitalized ACS patients with CKD?
Hazard Ratio: 2.02 (95% CI 1.26–3.27)
Absolute Event Rate: 46.2% vs 23.2%
p-value: p=<0.001
The CHA2DS2-VASc score is an independent predictor of all-cause mortality in CKD patients hospitalized with ACS, offering a simple and practical tool for early risk stratification.
Background Chronic kidney disease (CKD) patients have a high prevalence of coronary artery disease and a high risk of cardiovascular events. The present study assessed the value of the CHA 2 DS 2 -VASc score for predicting mortality among hospitalized acute coronary syndrome (ACS) patients with CKD. Methods This was a retrospective cohort study that included CKD patients who were hospitalized for ACS from January 2015 to May 2020. The CHA 2 DS 2 -VASc score for each eligible patient was determined. Patients were stratified into two groups according to CHA 2 DS 2 -VASc score: <6 (low) and ≥6 (high). The primary endpoint was all-cause mortality. Results A total of 313 eligible patients were included in the study, with a mean CHA 2 DS 2 -VASC score of 4.55 ± 1.68. A total of 220 and 93 patients were assigned to the low and high CHA 2 DS 2 -VASc score groups, respectively. The most common reason for hospitalization was unstable angina (39.3%), followed by non-ST-elevation myocardial infarction (35.8%) and ST-elevation myocardial infarction (24.9%). A total of 67.7% of the patients (212/313) received coronary reperfusion therapy during hospitalization. The median follow-up time was 23.0 months (interquartile range: 12–38 months). A total of 94 patients (30.0%) died during follow-up. The high score group had a higher mortality rate than the low score group (46.2 vs. 23.2%, respectively; p < 0.001). The cumulative incidence of all-cause death was higher in the high score group than in the low score group (Log-rank test, p < 0.001). Multivariate Cox regression analysis indicated that CHA 2 DS 2 -VASc scores were positively associated with all-cause mortality (hazard ratio: 2.02, 95% confidence interval: 1.26–3.27, p < 0.001). Conclusion The CHA 2 DS 2 -VASc score is an independent predictive factor for all-cause mortality in CKD patients who are hospitalized with ACS. This simple and practical scoring system may be useful for the early identification of patients with a high risk of death.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) conducted a cohort in Acute Coronary Syndrome with Chronic Kidney Disease (n=313). High CHA2DS2-VASc score (≥6) vs. Low CHA2DS2-VASc score (<6) was evaluated on All-cause mortality (HR 2.02, 95% CI 1.26-3.27, p=<0.001). A high CHA2DS2-VASc score (≥6) was independently associated with an increased risk of all-cause mortality compared to a low score (<6) in CKD patients hospitalized with ACS (HR 2.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: